近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
Lu, L., Su, S., Yang, H. *, Jiang, S*. Antivirals with Common Targets against Highly Pathogenic Viruses. Cell 2021 Mar 18;184(6):1604-1620.
Wang, J. #, Li P. #, Yu, Y. #, Fu, Y., Jiang, H., Lu, M., Sun, Z., Jiang, S, Lu, L.*, Wu, M.* Pulmonary Surfactant-Biomimetic Nanoparticles Potentiate Heterosubtypic Influenza Immunity. Science 2020 Feb 21;367(6480).
Liu, Z.#, Zhou, J#, Xu, W#., Deng, W. #, Wang, Y. #, Wang, M. #, Wang, Q., Hsieh, M., Dong, J., Wang, X., Huang, W., Xing, L., He, M., Tao, C., Xie, Y., Zhang, Y,. *, Wang, Y. *, Zhao, J. *, Yuan, ZH. *, Qin, C. *, Jiang, S.*, Lu, L.* A novel STING Agonist-Adjuvanted Pan-Sarbecovirus Vaccine Elicits Potent and Durable Neutralizing Antibody and T Cell Responses in Mice, Rabbits and NHPs. Cell Research. 2022. 32(3):269-287.
Wang, Q.#, Su, S#, Xue, J#., Yu, F., Pu, J., Bi, W., Xia, S., Meng, Y., Wang, C., Yang, W., Xu, W., Zhu, Y., Zheng, Q., Qin, C.*, Jiang, S.*, Lu, L.* An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells. Science Translational Medicine. 2020 12, eaaz2254.
Xia, S.#, Liu, M#, Wang, C#., Xu, W. #, Lan, Q., Feng, S., Qi, F., Bao, L., Du, L., Liu, S., Qin, C., Sun, F. *, Shi, Z. *, Zhu, Y. *, Jiang, S.*, Lu, L.* Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Research. 2020 Apr;30(4):343-355. (封面)
Xia, S.#, Chan, JW#, Wang, L#., Jiao, F., Chik, K., Lan, Q., Xu, W., Wang, Q., Wang, C., Yuen, KY.,*, Lu, L.* , Jiang, S.* Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. Cell Research. 2022. Apr;32(4):404-406.
Liu Z#, Chan Jasper Fuk-Woo#, Zhou J#, Wang M#, Wang Q, Zhang G, Xu W, Chik Kenn Ka-Heng, Zhang Y, Wang Y*, Yuen Kwok-Yung*, Lu L*, Jiang S*. A Pan-sarbecovirus Vaccine Induces Highly Potent and Durable Neutralizing Antibody Responses in Non-human Primates against SARS-CoV-2 Omicron Variant. Cell Research. 2022. Feb 24;1-3. doi: 10.1038/s41422-022-00631-z. Online ahead of print
Fang, Y. #, Liu, Z. #, Qiu, Y. #, Kong, J., Fu, Y., Liu, Y., Quan, J., Wang, Q., Xu, W., Yin, L., Cui, J., Curry, S., Jiang, S., Lu, L.*, Zhou, X*. Inhibition of viral suppressor of RNAi proteins by designer peptides protects from enteroviral infection in vivo. Immunity 2021 Oct 12;54(10):2231-2244.e6(封面)
Xia, S. #, Lan, Q. #, Zhu, Y. #, Wang, C. #, Xu, W. #, Li, Y., Wang, L., Jiao, F., Zhou, J., Hua, C., Wang, Q., Cai, X., Wu, Y., Gao, J., Liu, H., Sun, G., Münch, J., Kirchhoff, F., Yuan, Z. *, Xie, Y. *, Sun, F. *, Jiang, S. *, Lu, L*. Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation Signal Transduct Target Ther. 2021, 6(1):288.
Xia, S.#, Yan, L.#, Xu, W.#, Agrawal, A.S., Alsaissi, A., Tseng, C.T.K., Wang, Q., Du, L., Tan, W., Wilson, I.A.*, Jiang, S.*, Yang, B.*, Lu, L.* (2019). A pan-coronavirus Fusion Inhibitor Targeting the HR1 Domain of Human Coronavirus Spike. Science Advances. 2019 Apr 10;5(4):eaav4580